Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH for Portal Hypertension), a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the company's first-in-class, orally-active
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results
SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the third quarter ended September
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models SAN DIEGO, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc.
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2016, and
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Second Quarter 2016 Financial Results
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30,
View HTML
Toggle Summary Conatus to Present at JMP Securities Life Sciences Conference
SAN DIEGO, June 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities
View HTML
Toggle Summary Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates
Conference Call and Webcast Presentation at 8:00 a.m. ET Today
View HTML
Toggle Summary Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
- Continued Directional Improvements in Key Measures of Liver Function after Six Months - - First Drug to Demonstrate Liver Function Benefit in Patients with NASH Cirrhosis - - Conference Call and Webcast Presentation at 8:00 a.m. ET on Thursday, May 5 - SAN DIEGO, May 04, 2016 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results
SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31,
View HTML
Toggle Summary Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress™ 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona,
View HTML